The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Targeting CLDN18.2 with zolbetuximab in gastric and GEJ cancer
Nataliya Uboha, MD, PhD, UW Carbone Cancer Center, Madison, WI, discusses findings from the SPOTLIGHT trial (NCT03504397), a Phase III study evaluating zolbetuximab, a claudin 18.2 targeting monoclonal antibody, plus modified (m)FOLFOX6 chemotherapy compared to placebo plus mFOLFOX6 as treatment for gastric and gastroesophageal junction (GEJ) cancer. The primary endpoint, progression-free survival, was met in addition to overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
